Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.004600%
Abdominal pain lower07.01.05.0100.000336%Not Available
Abdominal pain upper07.01.05.0030.001824%
Abdominal tenderness07.01.05.0040.000224%Not Available
Acute hepatic failure09.01.03.0010.000616%Not Available
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000951%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000448%Not Available
Acute promyelocytic leukaemia16.01.05.003; 01.10.05.0030.000112%Not Available
Acute pulmonary oedema02.05.02.004; 22.01.03.0050.000112%Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.000728%
Acute respiratory failure22.02.06.001; 14.01.04.0040.000560%Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.0010.000112%
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agranulocytosis01.02.03.0010.000895%Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000672%Not Available
Amylase increased13.05.01.009--
Anaemia01.03.02.0010.008988%
Anaphylactic shock10.01.07.002; 24.06.02.0040.000336%Not Available
Antidiuretic hormone abnormality14.05.07.004; 05.03.03.0050.000112%Not Available
Anuria20.01.03.0020.000280%Not Available
Aortic aneurysm24.02.03.0010.000168%Not Available
Aortic stenosis24.04.01.0010.000302%Not Available
Aortic thrombosis24.01.09.0010.000672%Not Available
Apathy19.04.04.0020.000168%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000280%
Aphthous ulcer07.05.06.0020.000112%Not Available
Aptyalism07.06.01.0010.000112%Not Available
Arterial thrombosis24.01.01.0020.000560%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene